Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy for COVID-19 shots.

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...